Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects

Urothelial carcinoma (UC), or bladder cancer, is the most common cancer of the urinary tract with limited treatment options. A new clinical trial aims to see how this type of cancer reacts to olaparib, a drug designed to target cancers that have defective DNA-repair mechanisms in their cells by inhibiting the action of PARP, an enzyme that can repair breaks in DNA. Read more...

liver cancer

New therapies tested in mice provide a one-two punch for treating liver cancer

Nov 5, 2018

Biopharmaceutical agents that combine the precision of cancer-specific antibodies and the potency of drugs toxic to harmful cells are increasingly being used to treat cancer. A team in CCR has identified two such agents for liver cancer, which were both found to reduce tumor size and prolong survival in mice. Read more...

Vanja Lazarevic

NICHD press release features new paper from CCR investigator Vanja Lazarevic

Nov 2, 2018

The National Institute of Child Health and Human Development recently issued a press release on a new collaborative paper with Vanja Lazarevic, Ph.D., Investigator in the Experimental Immunology Branch, and others from institutes across NIH. The paper, “Regulation of myelin structure and conduction velocity by perinodal astrocytes,” suggests that astrocytes play an important role in how the brain processes information.  Read more...

NICHD press release features new paper from CCR investigator Vanja Lazarevic
Lung cancer cells

Lung Cancer Research

Nov 1, 2018

November is Lung Cancer Awareness Month. Our research portfolio includes investigators making important discoveries in lung cancer research.  Read more...

pancreatic cancer cells

Pancreatic Cancer Research

Nov 1, 2018

November is Pancreatic Cancer Awareness Month. We have many researchers, both in the basic and clinical disciplines, who are working on pancreatic cancer.  Learn more...

Christopher Kanakry, M.D.

Christopher Kanakry appointed as an NIH Lasker Scholar Tenure Track Investigator

Oct 26, 2018

Christopher Kanakry, M.D., has been appointed as an NIH Lasker Scholar Tenure Track Investigator in the Experimental Transplantation and Immunology Branch. Dr. Kanakry pursues basic, translational, and clinical research related to allogeneic hematopoietic cell transplantation. His work largely centers on better understanding and developing the use of post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Read more...

Christopher Kanakry appointed as an NIH Lasker Scholar Tenure Track Investigator
Jack Shern, M.D.

Jack Shern appointed as an NIH Lasker Scholar Tenure Track Investigator

Oct 26, 2018

Jack Shern, M.D., has been appointed as an NIH Lasker Scholar Tenure Track Investigator in the Pediatric Oncology Branch. Dr. Shern previously served as an Assistant Clinical Investigator in CCR's Clinical Investigator Development Program. Dr. Shern's research focuses on defining and developing precision therapies targeting the genetic mutations that drive tumorigenesis. Read more...

Jack Shern appointed as an NIH Lasker Scholar Tenure Track Investigator
Renal cell carcinoma

Clinical trial evaluates small molecule inhibitor in von Hippel-Lindau disease-associated renal cell carcinoma

Oct 26, 2018

Von Hippel-Lindau (VHL) disease is a hereditary condition that causes an increased risk of developing tumors in several organs, including the kidneys. A new clinical trial is testing a small molecule inhibitor drug to see if it can suppress specific protein activity and thus shrink renal cell carcinoma tumors. Read more...

non-Hodgkin lymphoma

Clinical trial tests multiple targeted agents for treatment of non-Hodgkin lymphoma

Oct 23, 2018

There are very few effective therapies for relapsed or refractory non-Hodgkin lymphoma (NHL), a fast-growing cancer that affects B cells. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch is leading CCR’s participation in a clinical trial to test the safety and effectiveness of two combination treatments to see if either combination can slow or stop the growth of lymphoma cells. Read more...

Perwez Hussain

Recap: The 5th NCI Pancreatic Cancer Symposium

Oct 15, 2018

The 5th NCI Pancreatic Cancer Symposium took place on October 2-3, 2018, and was attended by about 300 participants from across the United States and abroad. This year’s symposium was jointly organized by the NCI Pancreatic Cancer Interest Group and the Medical University of Gottingen, Germany. The symposium covered the latest advancements in the field and provided novel insights in the area of early detection, epidemiology, tumor biology including metabolic reprograming and inflammatory/immune signaling and tumor stromal interaction, and it highlighted the challenges in developing treatment strategies to improve patient outcomes.  Read more...

Chongyi Chen, Ph.D.

Chongyi Chen appointed as Stadtman Tenure Track Investigator

Oct 5, 2018

Chongyi Chen, Ph.D., has joined the Laboratory of  Biochemistry and Molecular Biology as a Stadtman Tenure Track Investigator. Dr. Chen joins us from Harvard University. His research focuses on the interface between DNA sequence, chromosome organization and gene expression in both bulk samples and single cells from a genome-wide perspective. Read more...

Chongyi Chen appointed as Stadtman Tenure Track Investigator

Pages